Skin Cancer | Oncology Newswatch

Encorafenib Combination May Provide New Treatment Option in Type of Melanoma

Encorafenib plus binimetinib demonstrates favorable efficacy compared with other treatment option for patients with BRAF-mutated melanoma.

Accredited CME from Imedex

Velocity Vlog: Advances in Merkel Cell Carcinoma - Therapeutic Advances and the Path Forward

This activity features Dr Paul Nghiem sharing emerging data and expert analysis about diagnosis, the emergence of immunotherapy as a viable therapeutic option, and the evolving standard of care for MCC.

Velocity Vlog: Advances in Merkel Cell Carcinoma - New Treatment Approaches

Featuring expert analysis by Dr Howard L. Kaufman of the Rutgers Cancer Institute, this activity contextualizes updates to the standard of care, relays the latest developments in immunotherapy, and offers insight into best practices for the incorporation of novel agents in your clinical practice.

Velocity Vlog: Advances in Merkel Cell Carcinoma - ASCO 2017 Update

Because Merkel cell carcinoma is a rare form of skin cancer that is seen far less frequently than melanoma, many oncologists have never encountered it in their medical practice.

Conferences

Biomarker Tied to Immunotherapy Response in Melanoma

Researchers at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy pembrolizumab.

News

Encorafenib Combination May Provide New Treatment Option in Type of Melanoma

Encorafenib plus binimetinib demonstrates favorable efficacy compared with other treatment option for patients with BRAF-mutated melanoma.

Adjuvant Vemurafenib Likely Not Optimal in Patients With Type of Resected Melanoma

A recent study analyzed the effectiveness of adjuvant vemurafenib in patients with resected, BRAFV600 mutation-positive melanoma

Obesity Associated With Improved Survival Outcomes in Metastatic Melanoma

Patients with metastatic melanoma and high body mass index have improved progression-free and overall survival rates compared with patients with normal BMI.

Age May Be a Factor in Facial Skin Cancer Treatment

In very elderly patients, less aggressive skin cancers on the face might not always need to be treated, a new study suggests.

Quiz

Factors Contributing to Melanoma Treatment Delay

According to a recent study published in JAMA Dermatology, which of the following factors do NOT contribute to treatment delay in melanoma?

Research in Review

Imaging Needed to Monitor Melanoma Brain Metastases During PD-1 Therapy

Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

The treatment of advanced melanoma represents a significant burden to the health system, and differs by insurance type and geographic location, according to the results of a regional analysis.

-----

Related Content

Resources

NCCN Announces Guideline Updates for Various Skin Cancers

The National Comprehensive Cancer Network released updated guidelines for the treatment of basal cell skin cancer, squamous cell skin cancer, and merkel cell carcinoma.

Subscribe to Skin Cancer